Showing results (51-60 of 80) with videos related to
Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapyJohn G Gribben, David P Ryan, Richard Boyajian, et al.Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.Cell|February 28, 2015
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapyJoan Montero, Kristopher A Sarosiek, Joseph D DeAngelo, et al.British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.Cell Reports|January 18, 2016
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian CancerYoung Eun Choi, Khyati Meghani, Marie-Eve Brault, et al.Ebiomedicine|November 11, 2017
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase InhibitorHuifeng Niu, Hyunjin Shin, Feng Gao, et al.The Journal of Clinical Investigation|April 26, 2014
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearanceRachel A Davidowitz, Laura M Selfors, Marcin P Iwanicki, et al.Pageof 8